Yixintang Pharmaceutical Group Co Ltd
SZSE:002727

Watchlist Manager
Yixintang Pharmaceutical Group Co Ltd Logo
Yixintang Pharmaceutical Group Co Ltd
SZSE:002727
Watchlist
Price: 22.65 CNY -0.4% Market Closed
Updated: May 19, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

16.6B
+2%
Assets
Growth Rates:
1 Year
+3%
3 Years
+78%
5 Years
+126%
7 Years
+177%
10 Years
+703%
8.9B
+5%
Liabilities
Growth Rates:
1 Year
+2%
3 Years
+150%
5 Years
+169%
7 Years
+153%
10 Years
+768%
7.7B
-2%
Equity
Growth Rates:
1 Year
+4%
3 Years
+34%
5 Years
+91%
7 Years
+210%
10 Years
+640%

Balance Sheet Decomposition
Yixintang Pharmaceutical Group Co Ltd

16.6B
Assets
8.9B
Liabilities
16.6B
Assets
8.9B
Liabilities
Current Assets 9.9B
Cash & Short-Term Investments 3B
Receivables 2B
Other Current Assets 4.9B
Non-Current Assets 6.8B
Long-Term Investments 164.9m
PP&E 4B
Intangibles 1.8B
Other Non-Current Assets 804.5m
Current Liabilities 7.2B
Accounts Payable 2.6B
Accrued Liabilities 568.3m
Short-Term Debt 2.4B
Other Current Liabilities 1.7B
Non-Current Liabilities 1.7B
Long-Term Debt 1.6B
Other Non-Current Liabilities 149.5m

Balance Sheet
Yixintang Pharmaceutical Group Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
1 056
1 034
1 595
2 196
961
983
1 044
1 662
2 859
2 987
Cash
0
0
1
1
1
0
0
1 662
2 859
2 987
Cash Equivalents
1 056
1 034
1 594
2 196
960
983
1 043
0
0
0
Short-Term Investments
0
0
210
0
614
930
1 433
297
8
0
Total Receivables
336
474
615
801
821
718
1 041
1 648
2 176
1 963
Accounts Receivables
245
325
404
597
606
523
812
1 350
1 727
1 437
Other Receivables
91
149
211
203
214
195
229
298
448
526
Inventory
766
1 024
1 373
1 626
1 866
2 028
2 195
3 317
3 387
3 853
Other Current Assets
240
482
600
373
796
948
1 006
768
1 027
1 091
Total Current Assets
2 399
3 014
4 393
4 996
5 057
5 608
6 718
7 692
9 458
9 893
PP&E Net
412
478
500
509
536
586
691
4 091
4 005
3 951
PP&E Gross
412
478
500
509
536
586
691
4 091
4 005
3 951
Accumulated Depreciation
134
180
231
282
334
385
440
1 506
2 178
2 958
Intangible Assets
29
65
88
83
85
91
123
123
166
184
Goodwill
2
497
796
1 058
1 077
1 061
1 102
1 380
1 397
1 650
Long-Term Investments
4
0
0
12
81
101
105
147
178
165
Other Long-Term Assets
96
140
236
489
521
517
590
904
976
804
Other Assets
2
497
796
1 058
1 077
1 061
1 102
1 380
1 397
1 650
Total Assets
2 941
N/A
4 194
+43%
6 013
+43%
7 147
+19%
7 356
+3%
7 963
+8%
9 328
+17%
14 337
+54%
16 179
+13%
16 647
+3%
Liabilities
Accounts Payable
363
562
881
942
1 302
1 411
1 799
2 334
2 633
2 560
Accrued Liabilities
68
66
71
167
223
251
314
251
431
568
Short-Term Debt
360
1 129
1 432
1 257
730
906
1 137
1 599
2 098
2 352
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
1 016
933
978
Other Current Liabilities
65
151
326
277
1 034
259
282
683
782
742
Total Current Liabilities
856
1 908
2 711
2 643
3 289
2 827
3 532
5 884
6 877
7 200
Long-Term Debt
0
0
794
797
0
483
0
1 764
1 759
1 552
Deferred Income Tax
0
0
0
0
0
18
0
4
4
4
Minority Interest
0
0
2
0
4
1
15
95
101
131
Other Liabilities
3
6
10
14
17
39
16
13
12
15
Total Liabilities
859
N/A
1 914
+123%
3 517
+84%
3 453
-2%
3 310
-4%
3 368
+2%
3 563
+6%
7 760
+118%
8 753
+13%
8 901
+2%
Equity
Common Stock
260
260
521
568
568
568
595
596
596
596
Retained Earnings
985
1 175
1 398
1 716
2 067
2 506
3 126
3 869
4 700
5 011
Additional Paid In Capital
838
845
578
1 410
1 410
1 409
2 097
2 157
2 147
2 144
Treasury Stock
0
0
0
0
0
0
53
47
23
4
Other Equity
0
0
1
0
1
112
0
3
6
0
Total Equity
2 083
N/A
2 280
+9%
2 496
+10%
3 694
+48%
4 046
+10%
4 595
+14%
5 765
+25%
6 578
+14%
7 426
+13%
7 746
+4%
Total Liabilities & Equity
2 941
N/A
4 194
+43%
6 013
+43%
7 147
+19%
7 356
+3%
7 963
+8%
9 328
+17%
14 337
+54%
16 179
+13%
16 647
+3%
Shares Outstanding
Common Shares Outstanding
521
521
521
568
568
568
590
591
591
591

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.